Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community.
Camilla Dalby Hansen, Johanne Kragh Hansen, Mads Israelsen...
https://pubmed.ncbi.nlm.nih.gov/40618958/Actively Recruiting
Led by Maja Thiele · Updated on 2022-09-01
6500
Participants Needed
1
Research Sites
513 weeks
Total Duration
Researchers are evaluating the use of transient elastography and other blood and imaging tests to detect advanced liver fibrosis in people at risk for liver diseases such as non-alcoholic fatty liver disease and alcoholic fatty liver disease. This prospective screening study at Odense University Hospital aims to assess how well transient elastography works as a screening tool by measuring its benefits, harms, detection rates, technical use, and ability to predict outcomes. The study includes a control group from the general population to compare findings. Participants include 3000 people at risk due to long-term alcohol overuse or metabolic syndrome with or without type 2 diabetes, along with 3500 from the general population. Everyone undergoes liver stiffness measurement using transient elastography while fasting. Those with elevated liver stiffness above 8.0 kiloPascal will have further tests including shear-wave elastography, abdominal ultrasound, and possibly a liver biopsy to confirm advanced fibrosis. After one year, participants with positive or at-risk results will have repeat tests, and those with increasing stiffness may be offered a second biopsy no sooner than two years after the first. During the study, participants will have liver stiffness measurements, blood tests for various fibrosis markers, and imaging studies. All participants will be followed for 10 years to monitor liver-related health outcomes and overall survival. The main outcomes measured are biopsy-confirmed advanced fibrosis at 5 years and liver-related events over 10 years, providing long-term insight into liver disease progression and the value of non-invasive screening methods.
CONDITIONS
Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers
M
Maja Thiele, MD, PhD, Professor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Maja Thiele
Lead Sponsor
Horizon 2020 - European Commission
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Initial assessment at enrollment
Participants undergo transient elastography and serum marker tests to assess liver stiffness and fibrosis as screening tools for advanced liver fibrosis.
1 visit (in-person)
Duration - Repeated assessments after a minimum of 1 year from inclusion, with follow-up for 10 years
Participants with elevated liver stiffness or at-risk participants receive repeated liver stiffness measurements and serum fibrosis marker tests at least one year after inclusion to monitor liver health.
Repeated visits at least 1 year apart and ongoing follow-up for 10 years
Duration - As needed, no earlier than 2 years after initial biopsy
Participants with elevated liver stiffness at follow-up may undergo liver biopsy to confirm advanced fibrosis, no earlier than two years after the initial biopsy.
1 visit (in-person) for biopsy and imaging assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Camilla Dalby Hansen, Johanne Kragh Hansen, Mads Israelsen...
https://pubmed.ncbi.nlm.nih.gov/40618958/Maria Kjaergaard, Katrine Prier Lindvig, Katrine Holtz Thorhauge...
https://pubmed.ncbi.nlm.nih.gov/37088311/Maja Thiele
Lead Sponsor
Horizon 2020 - European Commission
Collaborating Sponsor